Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies

被引：36

作者：

Burt, Richard ^{[1
]}

Warcel, Dana ^{[2
]}

Fielding, Adele K. ^{[1
]}

机构：

[1] UCL Canc Inst, 72 Huntley St, London WC1E 6DD, England

[2] UCLH, London, England

来源：

HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2019年 / 15卷 / 03期

关键词：

blinatumomab; acute lymphoblastic Leukaemia; B-cell non hodgkin Lymphoma; immunotherapeutics; ACUTE LYMPHOBLASTIC-LEUKEMIA; MINIMAL RESIDUAL DISEASE; RELAPSE-FREE SURVIVAL; NON-HODGKIN-LYMPHOMA; TERM-FOLLOW-UP; INOTUZUMAB OZOGAMICIN; ADULT PATIENTS; ELDERLY-PATIENTS; SINGLE-ARM; PHASE-II;

D O I：

10.1080/21645515.2018.1540828

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Blinatumomab (Blincyto, Amgen), a bi-specific antibody, is a first-in-class, targeted immunotherapy agent for treatment of B-cell malignancies with a novel mechanism of action which involves in-vivo engagement of the patient's T cells with CD19-expressing tumour cells. Clinical trials have demonstrated its efficacy in relapsed B-cell Acute Lymphoblastic Leukaemia (B-ALL) and B-cell Non-Hodgkin's Lymphoma including in patients who are refractory to chemotherapy. This review summarises the development and design of Blinatumomab, the outcome of clinical studies demonstrating its efficacy and how to manage the administration, practically, including relevant toxicities. We compare and contrast it to other emerging agents for treatment of B-cell malignancies.

引用

页码：594 / 602

页数：9

共 58 条

[11] Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study [J].

Goebeler, Maria-Elisabeth ;

Knop, Stefan ;

Viardot, Andreas ;

Kufer, Peter ;

Topp, Max S. ;

Einsele, Hermann ;

Noppeney, Richard ;

Hess, Georg ;

Kallert, Stefan ;

Mackensen, Andreas ;

Rupertus, Kathrin ;

Kanz, Lothar ;

Libicher, Martin ;

Nagorsen, Dirk ;

Zugmaier, Gerhard ;

Klinger, Matthias ;

Wolf, Andreas ;

Dorsch, Brigitte ;

Quednau, Beate D. ;

Schmidt, Margit ;

Scheele, Juergen ;

Baeuerle, Patrick A. ;

Leo, Eugen ;

Bargou, Ralf C. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (10) :1104-+

[12] Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia [J].

Goekbuget, N. ;

Kelsh, M. ;

Chia, V. ;

Advani, A. ;

Bassan, R. ;

Dombret, H. ;

Doubek, M. ;

Fielding, A. K. ;

Giebel, S. ;

Haddad, V. ;

Hoelzer, D. ;

Holland, C. ;

Ifrah, N. ;

Katz, A. ;

Maniar, T. ;

Martinelli, G. ;

Morgades, M. ;

O'Brien, S. ;

Ribera, J-M ;

Rowe, J. M. ;

Stein, A. ;

Topp, M. ;

Wadleigh, M. ;

Kantarjian, H. .

BLOOD CANCER JOURNAL, 2016, 6 :e473-e473

[13] Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia [J].

Goekbuget, Nicola ;

Dombret, Herve ;

Bonifacio, Massimiliano ;

Reichle, Albrecht ;

Graux, Carlos ;

Faul, Christoph ;

Diedrich, Helmut ;

Topp, Max S. ;

Brueggemann, Monika ;

Horst, Heinz-August ;

Havelange, Violaine ;

Stieglmaier, Julia ;

Wessels, Hendrik ;

Haddad, Vincent ;

Benjamin, Jonathan E. ;

Zugmaier, Gerhard ;

Nagorsen, Dirk ;

Bargou, Ralf C. .

BLOOD, 2018, 131 (14) :1522-1531

[14] Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia [J].

Goekbuget, Nicola ;

Zugmaier, Gerhard ;

Klinger, Matthias ;

Kufer, Peter ;

Stelljes, Matthias ;

Viardot, Andreas ;

Horst, Heinz A. ;

Neumann, Svenja ;

Brueggemann, Monika ;

Ottmann, Oliver G. ;

Burmeister, Thomas ;

Wessiepe, Dorothea ;

Topp, Max S. ;

Bargou, Ralf .

HAEMATOLOGICA, 2017, 102 (04) :E132-E135

[15] Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies [J].

Goekbuget, Nicola ;

Kneba, Michael ;

Raff, Thorsten ;

Trautmann, Heiko ;

Bartram, Claus-Rainer ;

Arnold, Renate ;

Fietkau, Rainer ;

Freund, Mathias ;

Ganser, Arnold ;

Ludwig, Wolf-Dieter ;

Maschmeyer, Georg ;

Rieder, Harald ;

Schwartz, Stefan ;

Serve, Hubert ;

Thiel, Eckhard ;

Brueggemann, Monika ;

Hoelzer, Dieter .

BLOOD, 2012, 120 (09) :1868-1876

[16] PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma [J].

Gopal, Ajay K. ;

Kahl, Brad S. ;

de Vos, Sven ;

Wagner-Johnston, Nina D. ;

Schuster, Stephen J. ;

Jurczak, Wojciech J. ;

Flinn, Ian W. ;

Flowers, Christopher R. ;

Martin, Peter ;

Viardot, Andreas ;

Blum, Kristie A. ;

Goy, Andre H. ;

Davies, Andrew J. ;

Zinzani, Pier Luigi ;

Dreyling, Martin ;

Johnson, Dave ;

Miller, Langdon L. ;

Holes, Leanne ;

Li, Daniel ;

Dansey, Roger D. ;

Godfrey, Wayne R. ;

Salles, Gilles A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (11) :1008-1018

[17] Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia [J].

Grupp, Stephan A. ;

Kalos, Michael ;

Barrett, David ;

Aplenc, Richard ;

Porter, David L. ;

Rheingold, Susan R. ;

Teachey, David T. ;

Chew, Anne ;

Hauck, Bernd ;

Wright, J. Fraser ;

Milone, Michael C. ;

Levine, Bruce L. ;

June, Carl H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (16) :1509-1518

[18] Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology Group [J].

Hunger, Stephen P. ;

Lu, Xiaomin ;

Devidas, Meenakshi ;

Camitta, Bruce M. ;

Gaynon, Paul S. ;

Winick, Naomi J. ;

Reaman, Gregory H. ;

Carroll, William L. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (14) :1663-1669

[19] Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia A Phase 2 Clinical Trial [J].

Jabbour, Elias ;

Ravandi, Farhad ;

Kebriaei, Partow ;

Huang, Xuelin ;

Short, Nicholas J. ;

Thomas, Deborah ;

Sasaki, Koji ;

Rytting, Michael ;

Jain, Nitin ;

Konopleva, Marina ;

Garcia-Manero, Guillermo ;

Champlin, Richard ;

Marin, David ;

Kadia, Tapan ;

Cortes, Jorge ;

Estrov, Zeev ;

Takahashi, Koichi ;

Patel, Yogin ;

Khouri, Maria R. ;

Jacob, Jovitta ;

Garris, Rebecca ;

O'Brien, Susan ;

Kantarjian, Hagop .

JAMA ONCOLOGY, 2018, 4 (02) :230-234

[20] Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study [J].

Kantarjian, Hagop ;

Ravandi, Farhad ;

Short, Nicholas J. ;

Huang, Xuelin ;

Jain, Nitin ;

Sasaki, Koji ;

Daver, Naval ;

Pemmaraju, Naveen ;

Khoury, Joseph D. ;

Jorgensen, Jeffrey ;

Alvarado, Yesid ;

Konopleva, Marina ;

Garcia-Manero, Guillermo ;

Kadia, Tapan ;

Yilmaz, Musa ;

Bortakhur, Gautam ;

Burger, Jan ;

Kornblau, Steven ;

Wierda, William ;

DiNardo, Courtney ;

Ferrajoli, Alessandra ;

Jacob, Jovitta ;

Garris, Rebecca ;

O'Brien, Susan ;

Jabbour, Elias .

LANCET ONCOLOGY, 2018, 19 (02) :240-248

← 1 2 3 4 5 6 →